Диабетическая Кардиомиопатия: Эпидемиология, Этиология И Патогенез

Serhiyenko, Victoria; Serhiyenko, A.A.

doi:10.22141/2224-0721.16.4.2020.208488

Cited by 2 publications

(1 citation statement)

References 73 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…Гіпертрофія ЛШ (ГЛШ), виявлена за допомогою ЕхоКГ, і фіброз міокарда є основними морфологічними ознаками, які характеризують ДКМП, що підтверджено результатами автопсії (наявність дифузного фіброзу і гіпертрофії міоцитів) [17]. Крім того, численні дослідження [22, 30 -35] підтвердили наявність ГЛШ, виявленої за допомогою ЕхоКГ, у популяції з ЦД ще на стадії порушення толерантності до глюкози [22,30,33,35]. У дослідженні Strong Heart Study виявлено незалежні асоціації порушення толерантності до глюкози зі збільшенням відносної товщини стінки ЛШ і ступеня ГЛШ [33].…”

Section: роль допплерехокардіографії у діагностиці ураження серцяunclassified

Diabetic cardiomyopathy: current state of the problem. Review

Кondratiuk¹,

Стахова²

2023

CE&ES

View full text Add to dashboard Cite

The literature review describes the evolution of views on diabetic cardiomyopathy (DCM): from a pathological condition with myocardial hypertrophy and fibrosis in patients with diabetes mellitus (DM) to the development of heart failure (HF) in the absence of other cardiovascular diseases (CVD). It has been demonstrated that DCM is a staged pathophysiological condition inherent in patients with DM and impaired glucose tolerance, caused by hyperglycemia, hyperinsulinemia, and insulin resistance, characterized by molecular changes, remodeling of the left chambers of the heart, a decrease in the systolic‑diastolic reserve of the ventricular myocardium, the development of HF, and is associated with dysfunction of the autonomic nervous system, disruption of energy metabolism and increased inflammation. The features of heart damage in both type 1 and type 2 DM were analyzed, and the importance of glycemic control to prevent the development and progression of HF was noted. The results of experimental and clinical studies (CARVAR 92 cohort, LIFE, RENAAL, the Framingham study, HyperGEN, the Strong Heart Study, RECORD trial, PRO active Study) gave the ground to claim that secondary DM prevention reduces the risks of death from CVD and the progression of pump function deterioration of the heart. Screening of DCM biomarkers (long non‑coding RNA and galectin‑3) and carrying out of Doppler echocardiography in patients with DM and impaired glucose tolerance will allow timely and adequate initiation of DCM treatment. Ways to correct changes in the heart that develop in patients with DM are given. Metformin, empagliflozin, canagliflozin, liraglutide, and semaglutide are listed as promising medications for drug correction of DCM.

show abstract

Section: роль допплерехокардіографії у діагностиці ураження серцяunclassified

Diabetic cardiomyopathy: current state of the problem. Review

Кondratiuk¹,

Стахова²

2023

CE&ES

View full text Add to dashboard Cite

show abstract

Diabetes mellitus and congestive heart failure

Serhiyenko

2022

Mìžnarodnij endokrinologìčnij žurnal

Self Cite

View full text Add to dashboard Cite

Congestive heart failure (CHF) is the final stage of cardiovascular disease and one of the leading causes of death. CHF develops in patients with the chronic coronary syndrome, hypertension, myocarditis, endocarditis, pericarditis, and other diseases. The prevalence of CHF in recent years is growing steadily and is about 2 % in the adult population. Among the factors that worsen the prognosis of CHF is diabetes mellitus (DM). Type 2 DM is an independent risk factor for heart failure (HF), and fasting plasma glucose and increased glycated hemoglobin A1c are significantly associated with an increased risk of HF. This review article summarizes the existing literature on the current state of the problem of DM and CHF. In particular, there are considered the issues related to the features of myocardial damage in type 2 DM, DM as a risk factor for HF, subclinical myocardial disorders in diabetic patients, HF as a risk factor for DM; pathophysiological features of DM and HF; classification of CHF (according to the New York Heart Association, the American College of Cardiology Foundation/American Heart Association, the European Society of Cardiology); diagnosis of CHF with preserved, reduced and mildly reduced left ventricular ejection fraction; principles of pathogenetic therapy of HF in DM, in particular, the appointment of drugs that affect the renin-angiotensin-aldosterone system (angiotensin-converting enzyme inhibitors, angiotensin II receptor blockers); sacubitril/valsartan; beta-adrenergic receptor blockers, mineralocorticoid receptor antagonists, sinus node inhibitors, sodium-glucose cotransporter type 2 inhibitors, diuretics. Treatment of a patient with DM and HF will be successful only if adequate and safe antidiabetic therapy is prescribed, on the one hand, and metabolically neutral pharmacological therapy, on the other.

show abstract

Диабетическая Кардиомиопатия: Эпидемиология, Этиология И Патогенез

Cited by 2 publications

References 73 publications

Diabetic cardiomyopathy: current state of the problem. Review

Diabetic cardiomyopathy: current state of the problem. Review

Diabetes mellitus and congestive heart failure

Contact Info

Product

Resources

About